This section lists the publications on research conducted as part of the NCER-PD, such as the Luxembourg Parkinson's Study. You can explore the list below, sorted by year, and for some publications, we have alredy made available a summary in English, German and French.

Guebila, M. B., & Thiele, I. (2016). Model-based dietary optimization for late-stage, levodopa-treated, Parkinson’s disease patients. Npj Systems Biology and Applications, 2(1). doi:10.1038/npjsba.2016.13 >> Read the summary

Heinzel, S., Roeben, B., Ben-Shlomo, Y., Lerche, S., Alves, G., Barone, P., Behnke, S., Berendse, H. W., Bloem, B. R., Burn, D., Dodel, R., Grosset, D. G., Hu, M., Kasten, M., Krüger, R., Moccia, M., Mollenhauer, B., Oertel, W., Suenkel, U., Walter, U., … Berg, D. (2016). Prodromal Markers in Parkinson's Disease: Limitations in Longitudinal Studies and Lessons Learned. Frontiers in aging neuroscience, 8, 147. https://doi.org/10.3389/fnagi.2016.00147

Krüger, R., Hilker, R., Winkler, C., Lorrain, M., Hahne, M., Redecker, C., Lingor, P., & Jost, W. H. (2016). Advanced stages of PD: interventional therapies and related patient-centered care. Journal of neural transmission (Vienna, Austria : 1996), 123(1), 31–43. https://doi.org/10.1007/s00702-015-1418-0 >> Read the summary

Weiss, D., Herrmann, S., Wang, L., Schulte, C., Brockmann, K., Plewnia, C., Gasser, T., Sharma, M., Gharabaghi, A., Krüger, R. (2016). Alpha-synuclein gene variants may predict neurostimulation outcome. Movement Disorders, 31(4), 601-603. doi:10.1002/mds.26558

Wüst, R., Maurer, B., Hauser, K., Woitalla, D., Sharma, M., & Krüger, R. (2016). Mutation analyses and association studies to assess the role of the presenilin-associated rhomboid-like gene in Parkinson's disease. Neurobiology of aging, 39, . https://doi.org/10.1016/j.neurobiolaging.2015.11.025

Antonini, A., Poewe, W., Chaudhuri, K. R., Jech, R., Pickut, B., Pirtošek, Z., Szasz, J., Valldeoriola, F., Winkler, C., Bergmann, L., Yegin, A., Onuk, K., Barch, D., Odin, P., Amalia, E., Arnold, G., Bajenaru, O., Bergmans, B., Bjornara, K. A., ... GLORIA study co-investigators (2017). Levodopa-carbidopa intestinal gel in advanced Parkinson's: Final results of the GLORIA registry. Parkinsonism and Related Disorders, 45, pp 13-20. https://doi.org/10.1016/j.parkreldis.2017.09.018

Ashrafi, A., Garcia, P., Kollmus, H., Schughart, K., del Sol, A., Buttini, M., Glaab, E. (2017) Absence of regulator of G-protein signaling 4 does not protect against dopamine neuron dysfunction and injury in the mouse 6-hydroxydopamine lesion model of Parkinson's disease, Neurobiology of Aging, 58, pp. 30, doi: 10.1016/j.neurobiolaging.2017.06.008

Blauwendraat, C., Faghri, F., Pihlstrom, L., Geiger, J. T., Elbaz, A., Lesage, S., May, P., Aude, N., Abramzon, Y., Murphy, N. A., Gibbs, J. R., Ryten, M., Ferrari, R., Bras, J., Guerreiro, R., Williams, J., Sims, R., Lubbe, S., Hernandez, D. G., Mok, K. Y., Robak, L., Camphell, R. H., Rogaeva, E., Traynor, B. J., Chia, R., Chung, S. J., International Parkinson’s Disease Genomics Consortium (IPDGC), COURAGE-PD Consortium, Glaab, E., Balling, R., Hardy, J. A., Brice, A., Houlden, H., Shulman, J. M., Morris, H. R., Gasser, T., Heutink, P., Krüger, R., Sharma, M., Simon-Sanchez, J., Nalls, M. A., Singleton, A. B., & Scholz, S. W. (2017) NeuroChip, an updated version of the NeuroX genotyping platform to rapidly screen for variants associated with neurological diseases. Neurobiology of Aging, 57, pp 247.e9-247.e13. https://doi.org/10.1016/j.neurobiolaging.2017.05.009

Bobbili, D. R., May, P., & Krüger, R. (2017). Rare variant analysis of the PPMI dataset to uncover the complex genetic architecture of Parkinson’s disease. Movement Disorders : Official Journal of the Movement Disorder Society, 322(Supplement S2), 405.

Burbulla, L. F., Song, P., Mazzulli, J. R., Zampese, E., Wong, Y. C., Jeon, S., Santos, D. P., Blanz, J., Obermaier, C. D., Strojny, C., Savas, J. N., Kiskinis, E., Zhuang, X., Krüger, R., Surmeier, D. J., & Krainc, D. (2017). Dopamine oxidation mediates mitochondrial and lysosomal dysfunction in Parkinson’s disease. Science, 357(6357), 1255-1261. https://doi.org/10.1126/science.aam9080 >> Read the summary

Fitzgerald, J. C., Zimprich, A., Carvajal-Berrio, D. A., Schindler, K. M., Maurer, B., Schulte, C., Bus, C., Hauser, A.-K., Kübler, M., Lewin, R., Bobbili, D. R., Schwarz, L. M., Vartholomaiou, E., Brockmann, K., Wüst, R., Madlung, J., Nordheim, A., Riess, O., Martins, L. M., Glaab, E., May, P., Schenke-Layland, K., Picard, D., Sharma, M., Gasser, T., & Krüger, R. (2017). Metformin reverses TRAP1 mutation-associated alterations in mitochondrial function in Parkinson's disease. Brain : A Journal of Neurology, 140(9), 2444-2459.

Glaab, E. (2017) Computational systems biology approaches for Parkinson's disease, Cell and Tissue Research (Special issue Parkinson's disease: Molecules, cells, and circuitries, T. Gasser, H. Braak, K. Del Tredici, Eds.), pp. 1, doi: 10.1007/s00441-017-2734-5

Kolber, P., Stallinger, C., & Krüger, R., (2017). Update zur intensivierten Therapie des fortgeschrittenen idiopathischen Parkinson-Syndroms, Nervenheilkunde, 36(8), pp. 647–654.

Krüger, R., Lingor, P., Doskas, T., Henselmans, J., Danielsen, E. H., de Fabregues, O., Stefani, A., Sensken, S. C., Parra, J. C., Onuk, K., Yegin, A., & Antonini, A. (2017). An Observational Study of the Effect of Levodopa-Carbidopa Intestinal Gel on Activities of Daily Living and Quality of Life in Advanced Parkinson's Disease Patients. Advances in therapy, 34(7), 1741–1752. https://doi.org/10.1007/s12325-017-0571-2

Krüger, R., Klucken, J., Weiss, D., Tönges, L., Kolber, P., Unterecker, S., Lorrain, M., Baas, H., Müller, T., & Riederer, P. (2017). Classification of advanced stages of Parkinson's disease: translation into stratified treatments. Journal of neural transmission (Vienna, Austria : 1996), 124(8), 1015–1027. https://doi.org/10.1007/s00702-017-1707-x >> Read the summary

Scholten, M., Klemt, J., Heilbronn, M., Plewnia, C., Bloem, B. R., Bunjes, F., Krüger, R., Gharabaghi, A., & Weiss, D. (2017). Effects of Subthalamic and Nigral Stimulation on Gait Kinematics in Parkinson's disease. Frontiers in neurology, 8, 543.

Seidel, K., Bouzrou, M., Heidemann, N., Krüger, R., Schols, L., den Dunnen, W. F. A., Korf, H.-W., & Rub, U. (2017). Involvement of the cerebellum in Parkinson disease and dementia with Lewy bodies. Annals of neurology, 81(6), pp. 898-903.

Straniero, L., Rimoldi, V., Samarani, M. et al. (2017). The GBAP1 pseudogene acts as a ceRNA for the glucocerebrosidase gene GBA by sponging miR-22-3p. Sci Rep, 7, 12702. https://doi.org/10.1038/s41598-017-12973-5

Trezzi, J., Galozzi, S., Jaeger, C., Barkovits, K., Brockmann, K., Maetzler, W., Berg, D., Marcus, K., Betsou, F., Hiller, K., Mollenhauer, B. (2017) Distinct Metabolomic Signature in Cerebrospinal Fluid in Early Parkinson’s Disease, Movement Disorders,10, pp. 1401, doi: 10.1002/mds.27132

Wang, L., Heckman, M. G., Aasly, J. O., Annesi, G., Bozi, M., Chung, S. J., Clarke, C., Crosiers, D., Eckstein, G., Garraux, G., Hadjigeorgiou, G. M., Hattori, N., Jeon, B., Kim, Y. J., Kubo, M., Lesage, S., Lin, J. J., Lynch, T., Lichtner, P., Mellick, G. D., Mok, V., Morrison, K. E., Quattrone, A., Satake, W., Silburn, P. A., Stefanis, L., Stockton, J. D., Tan, E. K., Toda, T., Brice, A., Van Broeckhoven, C., Uitti, R. J., Wirdefeldt, K., Wszolek, Z., Xiromerisiou, G., Maraganore, D. M., Gasser, T., Krüger, R., Farrer, M. J., Ross, O. A., & Sharma, M. (2017). Evaluation of the interaction between LRRK2 and PARK16 loci in determining risk of Parkinson's disease: analysis of a large multicenter study. Neurobiology of aging, 49, 217.e1-217.e4.

Blauwendraat, C., Reed, X., Kia, D. A., Gan-Or, Z., Lesage, S., Pihlstrøm, L., Guerreiro, R., Gibbs, J. R., Sabir, M., Ahmed, S., Ding, J., Alcalay, R. N., Hassin-Baer, S., Pittman, A. M., Brooks, J., Edsall, C., Hernandez, D. G., Chung, S. J., Goldwurm, S., Toft, M., … COURAGE-PD (Comprehensive Unbiased Risk Factor Assessment for Genetics and Environment in Parkinson’s Disease) Consortium, the French Parkinson’s Disease Consortium, and the International Parkinson’s Disease Genomics Consortium (IPDGC) (2018). Frequency of Loss of Function Variants in LRRK2 in Parkinson Disease. JAMA neurology, 75(11), 1416–1422. https://doi.org/10.1001/jamaneurol.2018.1885

Fitzgerald, J.C., Zimprich, A., Reddy Bobbili, D., Sharma, M., May, P., Krüger, R. (2018) Reply: No evidence for rare TRAP1 mutations influencing the risk of idiopathic Parkinson's disease. Brain, 141(3), p. e17, https://doi.org/10.1093/brain/awx380

Hipp, G., Vaillant, M., Diederich, N. J., Roomp, K., Satagopam, V. P., Banda, P., Sandt, E., Mommaerts, K., Schmitz, S. K., Longhino, L., Schweicher, A., Hanff, A. M., Nicolai, B., Kolber, P., Reiter, D., Pavelka, L., Binck, S., Pauly, C., Geffers, L., Betsou, F., … Krüger, R. (2018). The Luxembourg Parkinson's Study: A Comprehensive Approach for Stratification and Early Diagnosis. Frontiers in aging neuroscience, 10, p 326. https://doi.org/10.3389/fnagi.2018.00326

Klucken, J., Krüger, R., Schmidt, P., & Bloem, B. R. (2018). Management of Parkinson's Disease 20 Years from Now: Towards Digital Health Pathways. Journal of Parkinson's disease, 8(s1), S85–S94. https://doi.org/10.3233/JPD-181519

Larsen, S. B., Hanss, Z., & Krüger, R. (2018). The genetic architecture of mitochondrial dysfunction in Parkinson's disease. Cell and tissue research, 373(1), 21–37. https://doi.org/10.1007/s00441-017-2768-8

Lhommee, E., Wojtecki, L., Czernecki, V., Witt, K., Maier, F., Tonder, L., Timmermann, L., Halbig, T. D., Pineau, F., Durif, F., Witjas, T., Pinsker, M., Mehdorn, M., Sixel-Doring, F., Kupsch, A., Krüger, R., Elben, S., Chabardes, S., Thobois, S., Brefel-Courbon, C., Ory-Magne, F., Regis, J.-M., Maltete, D., Sauvaget, A., Rau, J., Schnitzler, A., Schupbach, M., Schade-Brittinger, C., Deuschl, G., Houeto, J.-L., & Krack, P. (2018). Behavioural outcomes of subthalamic stimulation and medical therapy versus medical therapy alone for Parkinson's disease with early motor complications (EARLYSTIM trial): secondary analysis of an open-label randomised trial. Lancet Neurol., 17(3), pp. 223-231. doi: 10.1016/S1474-4422(18)30035-8.

Riederer, P., Jellinger, K. A., Kolber, P., Hipp, G., Sian-Hülsmann, J., & Krüger, R. (2018). Lateralisation in Parkinson disease. Cell and tissue research, 373(1), 297–312. https://doi.org/10.1007/s00441-018-2832-z

Bolognin, S., Fossépré, M., Qing, X., Jarazo, J., Ščančar, J., Moreno, E. L., Nickels, S. L., Wasner, K., Ouzren, N., Walter, J., Grünewald, A., Glaab, E., Salamanca, L., Fleming, R., Antony, P., & Schwamborn, J. C. (2018). 3D Cultures of Parkinson's Disease-Specific Dopaminergic Neurons for High Content Phenotyping and Drug Testing. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 6(1), 1800927. https://doi.org/10.1002/advs.201800927

Glaab, E., Trezzi, J. P., Greuel, A., Jäger, C., Hodak, Z., Drzezga, A., Timmermann, L., Tittgemeyer, M., Diederich, N. J., & Eggers, C. (2019). Integrative analysis of blood metabolomics and PET brain neuroimaging data for Parkinson's disease. Neurobiology of disease, 124, 555–562. https://doi.org/10.1016/j.nbd.2019.01.003

Kishore, A., Ashok Kumar Sreelatha, A., Sturm, M., von-Zweydorf, F., Pihlstrøm, L., Raimondi, F., Russell, R., Lichtner, P., Banerjee, M., Krishnan, S., Rajan, R., Puthenveedu, D. K., Chung, S. J., International Parkinson's Disease Genomics Consortium (IPDGC), Comprehensive Unbiased Risk Factor Assessment for Genetics and Environment in Parkinson's Disease (COURAGE-PD), Bauer, P., Riess, O., Gloeckner, C. J., Kruger, R., Gasser, T., … Sharma, M. (2019). Understanding the role of genetic variability in LRRK2 in Indian population. Movement disorders : official journal of the Movement Disorder Society, 34(4), 496–505. https://doi.org/10.1002/mds.27558

Nickels, S.L., Walter, J., Bolognin, S., et al. (2019) Impaired serine metabolism complements LRRK2-G2019S pathogenicity in PD patients. Parkinsonism Relat. Disord., 67, pp.48–55.

Riederer, P., Berg, D., Casadei, N., Cheng, F., Classen, J., Dresel, C., Jost, W., Krüger, R., Müller, T., Reichmann, H., Rieß, O., Storch, A., Strobel, S., van Eimeren, T., Völker, H. U., Winkler, J., Winklhofer, K. F., Wüllner, U., Zunke, F., & Monoranu, C. M. (2019). α-Synuclein in Parkinson's disease: causal or bystander?. Journal of neural transmission (Vienna, Austria : 1996), 126(7), 815–840. https://doi.org/10.1007/s00702-019-02025-9

Schuepbach, W., Tonder, L., Schnitzler, A., Krack, P., Rau, J., Hartmann, A., Hälbig, T. D., Pineau, F., Falk, A., Paschen, L., Paschen, S., Volkmann, J., Dafsari, H. S., Barbe, M. T., Fink, G. R., Kühn, A., Kupsch, A., Schneider, G. H., Seigneuret, E., Fraix, V., … EARLYSTIM study group (2019). Quality of life predicts outcome of deep brain stimulation in early Parkinson disease. Neurology, 92(10), e1109–e1120. https://doi.org/10.1212/WNL.0000000000007037

Schymanski, E. L., Baker, N. C., Williams, A. J., Singh, R. R., Trezzi, J. P., Wilmes, P., Kolber, P. L., Kruger, R., Paczia, N., Linster, C. L., & Balling, R., (2019). Connecting environmental exposure and neurodegeneration using cheminformatics and high resolution mass spectrometry: potential and challenges. Environmental science. Processes & impacts, 21(9), 1426–1445. https://doi.org/10.1039/c9em00068b

Simons, J. A., Vaillant, M., Hipp, G., Pavelka, L., Stute, L., Pauly, C., & Krüger, R. (2019). Multilingual Validation of the First French Version of Munich Dysphagia Test-Parkinson's Disease (MDT-PD) in the Luxembourg Parkinson's Study. Frontiers in neurology, 10, 1180. https://doi.org/10.3389/fneur.2019.01180

Vollstedt, E. J., Kasten, M., Klein, C., & MJFF Global Genetic Parkinson's Disease Study Group (2019). Using global team science to identify genetic parkinson's disease worldwide. Annals of neurology, 86(2), 153–157. https://doi.org/10.1002/ana.25514

Antony, P.M.A., Kondratyeva, O., Mommaerts, K. et al. (2020) Fibroblast mitochondria in idiopathic Parkinson’s disease display morphological changes and enhanced resistance to depolarization. Sci Rep, 10, 1569. https://doi.org/10.1038/s41598-020-58505-6

Baldini, F., Hertel, J., Sandt, E., Thinnes, C. C., Neuberger-Castillo, L., Pavelka, L., Betsou, F., Krüger, R., & Thiele, I. (2020). Parkinson's disease-associated alterations of the gut microbiome predict disease-relevant changes in metabolic functions. BMC Biology, 18(1), 62. https://doi.org/10.1186/s12915-020-00775-7

Barbe, M. T., Tonder, L., Krack, P., Debû, B., Schüpbach, M., Paschen, S., Dembek, T. A., Kühn, A. A., Fraix, V., Brefel-Courbon, C., Wojtecki, L., Maltête, D., Damier, P., Sixel-Döring, F., Weiss, D., Pinsker, M., Witjas, T., Thobois, S., Schade-Brittinger, C., Rau, J., … EARLYSTIM study group (2020). Deep Brain Stimulation for Freezing of Gait in Parkinson's Disease With Early Motor Complications. Movement disorders : official journal of the Movement Disorder Society, 35(1), pp 82–90. https://doi.org/10.1002/mds.27892

Berenguer-Escuder, C., Grossmann, D., Antony, P., Arena, G., Wasner, K., Massart, F., Jarazo, J., Walter, J., Schwamborn, J. C., Grünewald, A., & Krüger, R. (2020). Impaired mitochondrial-endoplasmic reticulum interaction and mitophagy in Miro1-mutant neurons in Parkinson's disease. Human molecular genetics, 29(8), 1353–1364. https://doi.org/10.1093/hmg/ddaa066

Bobbili, D.R., Banda, P., Krüger, R., May, P. (2020) Excess of singleton loss-of-function variants in Parkinson's disease contributes to genetic risk. Journal of Medical Genetics, 57(9), pp 617-623. https://doi.org/10.1136/jmedgenet-2019-106316.

Hanss, Z., Boussaad, I., Jarazo, J., Schwamborn, J. C., & Krüger, R. (2020). Quality Control Strategy for CRISPR-Cas9-Based Gene Editing Complicated by a Pseudogene. Frontiers in genetics, 10, 1297. https://doi.org/10.3389/fgene.2019.01297

Larsen, S.B., Hanss, Z., Cruciani, G., Massart, F., Barbuti, P.A., Mellick, G., Krüger, R. (2020) Induced pluripotent stem cell line (LCSBi001-A) derived from a patient with Parkinson's disease carrying the p.D620N mutation in VPS35.  Stem Cell Res, 45, 101776. https://doi.org/10.1016/j.scr.2020.101776.

Monzel, A. S., Hemmer, K., Kaoma, T., Smits, L. M., Bolognin, S., Lucarelli, P., Rosety, I., Zagare, A., Antony, P., Nickels, S. L., Krueger, R., Azuaje, F., & Schwamborn, J. C. (2020). Machine learning-assisted neurotoxicity prediction in human midbrain organoids. Parkinsonism & related disorders, 75, 105–109. https://doi.org/10.1016/j.parkreldis.2020.05.011

Ohnmacht, J., May, P., Sinkkonen, L., & Krüger, R. (2020). Missing heritability in Parkinson's disease: the emerging role of non-coding genetic variation. Journal of neural transmission (Vienna, Austria : 1996), 127(5), 729–748. https://doi.org/10.1007/s00702-020-02184-0

Stute, L., & Krüger, R. (2020). [Emerging concepts for precision medicine in Parkinson's disease with focus on genetics]. Fortschritte Der Neurologie-Psychiatrie. https://doi.org/10.1055/a-1149-2204.

Woitalla D, Krüger R, Lorenzl S, et al. (2020) [The role of inhibitors of COMT and MAO-B in the therapy of Parkinson's disease]. Fortschritte der Neurologie-psychiatrie. https://doi.org/10.1055/a-1149-9308